Regulatory approval

Published by the European Medicines Agency.

The European Medicines Agency (EMA) has authorized ramucirumab in combination with erlotinib as a first-line treatment for adult patients with metastatic non-small cell lung cancer with activating EGFR variants.

This is written in the approval document as:

Cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.

Citation

Eli Lilly Nederland B.V. Cyramza (ramucirumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf. Revised December 2022. Accessed March 7, 2024.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
EMA (1)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab